<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03145051</url>
  </required_header>
  <id_info>
    <org_study_id>Laboratoiredelamer</org_study_id>
    <nct_id>NCT03145051</nct_id>
  </id_info>
  <brief_title>Efficacy of Nasal Irrigation With Respimer® Netiflow® vs Saline Among Patients With Cystic Fibrosis and Chronic Rhinosinusitis</brief_title>
  <acronym>Respire</acronym>
  <official_title>Prospective, Randomized, Cross-over, Multicenter, Trial Comparing the Efficacy and Tolerability of Nasal Irrigation With Respimer® Netiflow® Mineral Salts Solution Versus Saline Among Patients With Cystic Fibrosis and Suffering From Chronic Rhinosinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire de la Mer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoire de la Mer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, cross-over, multicenter, trial comparing the efficacy and
      tolerability of nasal irrigation with Respimer® mineral salts solution versus saline solution
      both administered with Respimer® Netiflow® medical device among patients aged ≥ 11 years and
      older with cystic fibrosis and suffering from chronic rhinosinusitis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quality of life among subjects undergoing nasal irrigation with Respimer® Netiflow® mineral salts solution compared to saline solution between inclusion and the end of treatment period.</measure>
    <time_frame>over an 8 weeks period</time_frame>
    <description>Quality of life to be assessed over an 8 weeks period of nasal wash using SNOT-20 questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical status evolution among subjects undergoing nasal irrigation with Respimer® Netiflow® mineral salts solution to saline solution between inclusion and the end of treatment period.</measure>
    <time_frame>over an 8 weeks period</time_frame>
    <description>Clinical status to be assessed after 4 and 8 weeks of nasal wash using Lund-Kennedy Symptomatic Score (LKSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic status evolution among subjects undergoing nasal irrigation with Respimer® Netiflow® mineral salts solution to saline solution between inclusion and the end of treatment period.</measure>
    <time_frame>over an 8 weeks period</time_frame>
    <description>Endoscopic status to be assessed after 4 and 8 weeks of nasal wash using Lund-Kennedy Endoscopic Score (LKES)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucociliary transport change among subjects undergoing nasal irrigation with Respimer® Netiflow® mineral salts solution to saline solution between inclusion and the end of treatment period.</measure>
    <time_frame>over an 8 weeks period</time_frame>
    <description>Mucociliary transport to be assessed after 4 and 8 weeks of nasal wash using saccharine test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of nasal bacterial pathogens among subjects undergoing nasal irrigation with Respimer® Netiflow® mineral salts solution to saline solution between inclusion and the end of treatment period.</measure>
    <time_frame>over an 8 weeks period</time_frame>
    <description>Evolution of nasal bacterial pathogens to be assessed by bacteriologic swab within ethmoid nasal cavities after 4 and 8 weeks of nasal wash</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient treatment acceptance of nasal irrigation with Respimer® Netiflow® medical device</measure>
    <time_frame>over an 8 weeks period</time_frame>
    <description>Patient treatment acceptance to be assessed by Morisky score after 4 and 8 weeks of nasal wash</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events : taste impairment, epistaxis, nasal irritations, nasal burning</measure>
    <time_frame>over an 8 weeks period</time_frame>
    <description>Adverse events to be assessed based on vigilance tracking during the whole study period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Chronic Rhinosinusitis</condition>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Respimer Netiflow mineral salts solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal irrigation with Respimer Netiflow mineral salts solution, 4 times/day during 8 weeks using Respimer Netiflow class I medical device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasal irrigation with saline solution , 4 times/day during 8 weeks using Respimer Netiflow class I medical device</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>a nasal irrigation care</description>
    <arm_group_label>Saline solution</arm_group_label>
    <other_name>nasal irrigation care</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Respimer Netiflow</intervention_name>
    <description>a nasal irrigation care</description>
    <arm_group_label>Respimer Netiflow mineral salts solution</arm_group_label>
    <other_name>nasal irrigation care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Patient with Cystic Fibrosis with or without lung transplant;

               -  Patients with allergic chronic rhino sinusitis or no allergic diagnosed by the
                  clinical investigator on the basis of the following signs in variable
                  combination: nasal congestion, headache, sneezing, itchy nose and eyes, runny
                  nose, nosebleeds and nasal crusts, redness and eye discharge present more than 3
                  months per year.

               -  Patient treated on an outpatient basis;

               -  Patient agreeing not to take sea baths for the duration of the study;

               -  Patient agreeing to respect the procedures for conducting the study, in
                  particular the washout period and follow-up visits;

               -  Patient capable of understanding and self-completing the questionnaires;

               -  For juvenile patients, the holder (s) of parental authority have accepted the
                  participation of the young person (by signing the informed consent after having
                  taken note of the information note)

               -  Member or beneficiary of a social security program

        Exclusion Criteria:

          -  Patients with significant obstruction of the nasal passages due to:

          -  a mucocele,

          -  polyposis causing nasal obstruction&gt; 90% or

          -  severe malformation of the septum causing a nasal obstruction&gt; 90% in whom surgical
             treatment is recommended;

               -  Patients with signs of severity that may require hospitalization, such as: severe
                  impairment of general health, dyspnoea with cyanosis, high fever (&gt; 40 ° C).

               -  Patients requiring corticosteroid therapy during the study, with the exception of
                  patients who received pulmonary transplant and were treated with oral
                  corticosteroids at no more than 0.2 mg / kg / day.

               -  Patients with known systemic immunodeficiency status with the exception of
                  patients receiving pulmonary transplantation and immunosuppressed.

               -  Patient pregnant (urine test) or without effective contraception (birth control
                  pill, contraceptive patch, contraceptive implant, vaginal ring, intrauterine
                  device or intrauterine device, male condom).

               -  Nursing patient.

               -  Patient with a contraindication to nasal irrigations as defined in the product
                  leaflet.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ORL et Chirurgie Cervico-faciale Centre Hospitalier Intercommunal (CHI) de Créteil</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2016</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>saline solution</keyword>
  <keyword>minerals</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>chronic rhinosinusitis</keyword>
  <keyword>nasal irrigation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

